Does interference with the renin–angiotensin system protect against diabetes? Evidence and mechanisms
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Agents interfering with the renin–angiotensin system (RAS) were consistently shown to lower the incidence of type 2 diabetes mellitus (T2DM), as compared to other antihypertensive drugs, in hypertensive high‐risk populations. The mechanisms underlying this protective effect of RAS blockade using angiotensin‐converting enzyme inhibitors or angiotensin‐receptor blockers on glucose metabolism are not fully understood. In this article, we will review the evidence from randomized controlled trials and discuss the proposed mechanisms as to how RAS interference may delay the onset of T2DM. In particular, as T2DM is characterized by β ‐cell dysfunction and obesity‐related insulin resistance, we address the mechanisms that underlie RAS blockade‐induced improvement in β ‐cell function and insulin sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“nl moderate exercise of at least 30 min a day, reduced the incidence of T2DM by 58% in individuals at high risk to develop T2DM [6].”
BackgroundDiabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 1×
“Although lifestyle intervention delayed the onset of T2DM, the Diabetes Prevention Program Outcomes Study showed that after 10 years the cumulative incidence of T2DM was still approximately 40% in the lifestyle intervention group [7].”
BackgroundLong-term mortality after gastric bypass surgery
Adams, T. D., Gress, R. E., Smith, S. C., Halverson, R. C., Simper, S. C., Rosamond, W. D., LaMonte, M. J., Stroup, A. M., & Hunt, S. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066603 · Cited by 2,572 · cited 1×
“Also, in this context, the dramatic effects of bariatric surgical procedures should be mentioned, which were shown to resolve T2DM in morbidly obese patients with T2DM [11,12].”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Physiology of Local Renin-Angiotensin Systems
Paul, M., Poyan Mehr, A., & Kreutz, R. (2006) · Physiological Reviews · doi:10.1152/physrev.00036.2005 · Cited by 1,739 · cited 9×
“Activation of the AT2R may counteract the differentiating effect of AngII, which is mainly mediated by the AT1R [102].”
BackgroundInfluentialMechanism of free fatty acid-induced insulin resistance in humans.
Roden, M., Price, T. B., Perseghin, G., Petersen, K. F., Rothman, D. L., Cline, G. W., & Shulman, G. I. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118742 · Cited by 1,539
Evans, J. L., Goldfine, I. D., Maddux, B. A., & Grodsky, G. M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.1 · Cited by 1,482
Weyer, C., Foley, J. E., Bogardus, C., Tataranni, P. A., & Pratley, R. E. (2000) · Diabetologia · doi:10.1007/s001250051560 · Cited by 799
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737 · cited 1×
“Recently, two large-scale prospective trials (the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication, DREAM trial [38] and the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research, NAVIGATOR trial [39]) specifically”
BackgroundEffect of valsartan on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001121 · Cited by 660 · cited 1×
“Recently, two large-scale prospective trials (the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication, DREAM trial [38] and the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research, NAVIGATOR trial [39]) specifically”
Background
Cited by
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
Donath, M. Y., Dalmas, É., Sauter, N. S., & Böni-Schnetzler, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.001 · Cited by 338
Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
Pollack, R. M., Donath, M. Y., LeRoith, D., & Leibowitz, G. (2016) · Diabetes Care · doi:10.2337/dcs15-3015 · Cited by 262
Effects of aldosterone on insulin sensitivity and secretion
Luther, J. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.08.016 · Cited by 114
Scoville, D. W., Cyphert, H. A., Liao, L., Xu, J., Reynolds, A., Guo, S., & Stein, R. (2015) · Diabetes · doi:10.2337/db15-0281 · Cited by 64
Metadata
- Authors
- van der Zijl, N. J., Moors, C. C. M., Goossens, G. H., Blaak, E. E., & Diamant, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2012-02-13
- Volume
- 14
- Issue
- 7
- Pages
- 586-595
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2160203698
- Cited by
- 35
- References
- 29
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Does interference with the renin–angiotensin system protect against diabetes? Evidence and mechanisms. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01559.x
- The paper
- van der Zijl, N. J., Moors, C. C. M., Goossens, G. H., Blaak, E. E., & Diamant, M. (2012). Does interference with the renin–angiotensin system protect against diabetes? Evidence and mechanisms. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01559.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.